The FASEB Journal · 2019 · 63 citations · 29 references
MedicineGynecologyOncologyGynecologic OncologyMolecular OncologyTumor ProgressionCancer BiomarkersCancer Cell SignalingCell-cycle DysregulationCyclin-dependent KinasesOvarian CancerCancer-associated Cyclin-dependent KinasesCyclin-dependent Kinase 9Cyclin-dependent Kinase InhibitorsOvarian Cancer BiomarkersOvarian Cancer MetastasisOvarian Cancer Prognostic BiomarkersRecurrent Ovarian CancerTherapeutic Cyclin-dependent Kinase Inhibition
Despite surgical and chemotherapeutic advances over the past few decades, the prognosis for ovarian cancer remains very poor. Although cyclin-dependent kinase (CDK) 9 has an established pathogenic role in various cancers, its function in ovarian cancer remains poorly defined. The purpose of this study was to evaluate the expression of CDK9 and its therapeutic potential in ovarian cancer. CDK9 expression was determined by immunohistochemistry in a unique ovarian cancer tissue microarray constructed with paired primary, metastatic, and recurrent tumor tissues from 26 ovarian cancer patients. CDK9 was highly expressed in human ovarian cancer cell lines and was also elevated in metastatic and recurrent ovarian tumor tissue compared with patient-matched primary ovarian tumor tissue. In addition, increased CDK9 significantly correlated with poor patient prognosis. Inhibition of CDK9 by small interfering RNA or CDK9 inhibitor functionally suppressed RNA transcription elongation, induced apoptosis, and reduced proliferation of ovarian cancer cells. Inhibition of CDK9 also suppressed ovarian cancer cell spheroid growth, clonogenicity formation, and migration activity. Our results reveal CDK9 as a novel prognostic biomarker and a promising therapeutic target for preventing metastasis and recurrence while also improving the overall clinical outcome for ovarian cancer patients.-Wang, J., Dean, D. C., Hornicek, F. J., Shi, H., Duan, Z. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
29
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller, Rebecca L. Siegel, Chun Chieh Lin et al. · CA A Cancer Journal for Clinicians · 2016 · 6.2K citations · Full text
Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations
Medicine, Oncology, Pharmacology +17
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
Rong Chen, Michael J. Keating, Varsha Gandhi et al. · Blood · 2005 · 254 citations · Full text
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Hanghang Zhang, Somnath Pandey, Meghan Travers et al. · Cell · 2018 · 228 citations · Full text